Anita Laugaland

Summary

Affiliation: Stavanger University Hospital
Country: Norway

Publications

  1. ncbi Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, Stavanger N 4068, Norway
    J Neurol Neurosurg Psychiatry 84:537-43. 2013
  2. ncbi Epidemiology of Parkinson's disease
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    J Neurol 255:18-32. 2008
  3. ncbi Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study
    G Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, N 4068 Stavanger, Norway
    J Neurol Neurosurg Psychiatry 80:851-7. 2009
  4. ncbi CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    J Neurol Neurosurg Psychiatry 81:1080-6. 2010
  5. ncbi Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study
    D Aarsland
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO 8100, N 4068 Stavanger, Norway
    Neurology 72:1121-6. 2009
  6. ncbi The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study
    H Vefring
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    Acta Neurol Scand 122:438-41. 2010

Collaborators

Detail Information

Publications6

  1. ncbi Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, Stavanger N 4068, Norway
    J Neurol Neurosurg Psychiatry 84:537-43. 2013
    ..This makes the PIGD complex an attractive target for the discovery of prognostic biomarkers in PD...
  2. ncbi Epidemiology of Parkinson's disease
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    J Neurol 255:18-32. 2008
    ....
  3. ncbi Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study
    G Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, N 4068 Stavanger, Norway
    J Neurol Neurosurg Psychiatry 80:851-7. 2009
    ....
  4. ncbi CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study
    Guido Alves
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    J Neurol Neurosurg Psychiatry 81:1080-6. 2010
    ..The authors investigated whether AD-related CSF protein levels are altered and relate to neuropsychological performance in early, untreated PD...
  5. ncbi Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study
    D Aarsland
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO 8100, N 4068 Stavanger, Norway
    Neurology 72:1121-6. 2009
    ..The aim of this study was to explore the proportion with mild cognitive impairment (MCI) and subtypes in an incidence cohort of untreated PD in Southern and Western Norway...
  6. ncbi The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study
    H Vefring
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    Acta Neurol Scand 122:438-41. 2010
    ..However, there have been conflicting reports on associations between APOE alleles and Parkinson's disease (PD) and age at onset in PD. There exist no data on APOE alleles in an unselected cohort of patients with incident PD...